Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 5Phase 4 4Phase 1/2 4Phase NA 3Phase 2/3 1

Status

Completed 19Recruiting 8Active not recruiting 8Unknown 7Not yet recruiting 5Withdrawn 2

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 3Neoplasm Metastasis 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Advanced Endometrial Cancer 1

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × lenvatinib × Clear all
NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Tongji Hospital

Phase 3 Not yet recruiting
400 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
198 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Tongji Hospital

Phase 3 Not yet recruiting
104 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡